Areas of Research
Scientists in the MORL have contributed to this body of work in many ways and continue to focus on defining the different mechanisms that underlie aHUS and C3G to develop more refined diagnostic and treatment algorithms, resolve questions of phenotypic variability, and provide more precise patient care.
Thrombotic Microangiopathies (TMA)
It is now clear that distinctly different mechanisms underlie the pathophysiology of this group of diseases.
Complement-Mediated TMA (aHUS)
Establishing the role of complement in aHUS has led to the development of anti-complement therapies that have improved patient outcome to such an extent that for children and adults with atypical HUS / complement-mediated TMA long-term health is now a reality.
C3 Glomerulopathy (C3G)
C3 Glomerulopathy (C3G) is the new designation for the group of glomerular diseases characterized by a dominant C3 immunofluorescence pattern on renal biopsy. Two major subgroups of C3G exist and are resolved by electron microscopy: Dense Deposit Disease (DDD) and C3 Glomerulonephritis (C3GN).